City Therapeutics, Bausch + Lomb enter strategic collaboration for GA treatment
Click Here to Manage Email Alerts
Key takeaways:
- City will develop an RNAi-based treatment for geographic atrophy.
- City received an upfront cash payment and is entitled to further payments if Bausch + Lomb pursues development.
City Therapeutics and Bausch + Lomb have entered into a strategic collaboration focused on the development of an RNA interference-based treatment for geographic atrophy, according to a press release.
City will use its RNA interference (RNAi) engineering technologies to develop a candidate that can be injected intravitreally, while Bausch + Lomb will be responsible for investigational new drug application-enabling studies and clinical development as well as regulatory submissions and commercialization activities.
In addition to an upfront cash payment, City is eligible for contingent payments tied to development, regulatory, commercial and sales milestones of up to $485 million as well as tiered royalty payments on net product sales should Bausch + Lomb decide to pursue the candidate for further development.
“City Therapeutics’ leadership is behind some of the biggest innovations in RNAi medicines to date, and they have the right experience to help us successfully disrupt the GA treatment landscape,” Brent Saunders, chairman and CEO of Bausch + Lomb, said in the release. “Today’s approved treatments for GA leave enormous room for improvement. Our plan is to develop a novel RNAi-based medicine through this collaboration that will deliver new hope and better outcomes for this large patient population.”
Read more about
Click Here to Manage Email Alerts